Research Projects & Grants

For Profit Organization

• A randomized, double-blind, placebo-controlled, phase 3 study to evaluate the efficacy, safety, and tolerability of JNJ-27018966 in the treatment of patients with diarrhea-predominant irritable bowel syndrome, Role: Investigator, Furiex Pharmaceuticals, (07/2012 - 07/2013) Status: Completed
• A multicenter, randomized, placebo-controlled, doubleblinded study of the efficacy and safety of lubiprostone in patients with opioid-induced bowel dysfuction, Role: Investigator, Sucampo Pharmaceuticals, Inc., (01/2009 - 01/2010) Status: Completed

Internal

• Prevalence of 30-day readmission rates for patients discharged from acute care hospital on parenteral nutrition, Role: Investigator, LLU Dept. of Medicine, (09/2019) Status: Approved